An Inactivated Cell-Culture Vaccine against Yellow FeverArchived
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
No association found between pandemic influenza vaccination and Guillain-Barre Syndrome in EuropeArchived
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.
Monitoring and assessing vaccine safety: A European perspective
Lopalco, P. L., Johansen, K., Ciancio, B., De Carvalho Gomes, H., Kramarz, P., Giesecke, J.
Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, july 2017 to March 2018
Gossner, C.M., Haussig, J.M., de Bellegarde de Saint Lary, C., Kaasik Aaslav, K., Schlagenhauf, P., Sudre, B.
Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: Multinational case-control study in Europe
Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., Sturkenboom, M.